Brought to you by www.DealSearchOnline.com
February 4, 2013 Issue:
Recent Health Care M&A Deals
Spotlight On: Pharmaceuticals
Spotlight on: Medical Devices
Webcast Calendar
Recent Health Care M&A Deals
HOSPITALS
Acquirer
Target
Price
Bangkok Dusit Medical Services
Krungdhon Hospital
$23.4 million
LABORATORIES, MRI AND DIALYSIS
Acquirer
Target
Price
JLL Partners
Bioclinica, Inc and CoreLab Partners
$123 million for Bioclinica
MEDICAL DEVICES
Acquirer
Target
Price
Solta Medical, Inc.
Sound Surgical
$30.5 million
PHARMACEUTICALS
Acquirer
Target
Price
Pharmascience
Rivex Pharma division
up to $8.5 million
Del Mar Pharmaceuticals (BC) Ltd.
DelMar Pharmaceuticals, Inc.
$1.83 million
HCC Best Practices for Proactive Medical Management
March 18-19, 2013 – Sheraton Music City Hotel – Nashville, TN
We are pleased to announce our 4th Annual HCC Best Practices conference. This conference will build on the success of the 2011 and 2012 conferences while providing practical, timely updates to help you continue to evolve your medical management practices with sound HCC coding.
www.opalevents.org/trk/hccb1301.html
Spotlight on: Pharmaceuticals
Pernix Therapeutics Holdings Inc. (NYSE: PTX) is another company on an acquisition roll. Following its November announcement of a dual purchase—Cypress Pharmaceuticals and Hawthorn Pharmaceuticals—Pernix announced its $25 million, stock-for-stock bid for Somaxon Pharmaceuticals, Inc…….Read more
NEW- The Health Care Services Acquisition Report, 19th Edition – Preorder Today!
Deals have been made. The 2013 Health Care Services Acquisition Report contains private deals in this market that are too small to make it into the financial press. Take advantage of our limited 2-for-1 offer – preorder The 2013 Health Care Services Acquisition Report by March 31st and receive The 2012 Health Care Services Acquisition Report FREE ($595 value)! Now that’s a recession resistant deal. Go to http://www.levinassociates.com/hardescription or call 800-248-1668 to preorder today!
Spotlight on: Medical Devices
With more than 2 million patients on some form of dialysis around the world, and dialysis treatment rates rising more than 5% annually, it isn’t hard to discern the reasoning behind Baxter International’s (NYSE: BAX) $4 billion bid for Gambro AB, a privately held dialysis product company based in Lund, Sweden…..Read more
Conference Calendar…Click here to see more
